Xenon Pharmaceuticals (XENE) Assets Average (2014 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Assets Average of $1.0 billion for Q1 2026, up 31.05% year-over-year from $770.7 million in Q1 2025, and up 62.77% quarter-over-quarter from $620.5 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Assets Average (2014 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Assets Average for 13 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 31.05% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 31.05% YoY), while the FY2025 annual figure was $715.7 million, down 18.81% from the prior year.
- Assets Average climbed to $1.0 billion in Q1 2026 per XENE's latest filing, from $620.5 million in the prior quarter.
- Across five years, Assets Average topped out at $1.0 billion in Q1 2026 and bottomed at $565.0 million in Q1 2022.
- Historically, Assets Average has averaged $765.4 million across 5 years, with a median of $765.0 million in 2022.
- Annual changes were most pronounced in 2022 — Assets Average surged 193.69% — and 2025, when it dropped 25.45%.
- Xenon Pharmaceuticals' Assets Average stood at $765.0 million in 2022, then advanced by 6.92% to $817.9 million in 2023, then fell by 0.11% to $817.0 million in 2024, then dropped by 24.05% to $620.5 million in 2025, then soared by 62.77% to $1.0 billion in 2026.
- Business Quant data shows XENE's Assets Average at $1.0 billion in Q1 2026, $620.5 million in Q4 2025, and $641.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 1.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.34 Bn |
| Mar 31, 2026 | 1.01 Bn |
| Dec 31, 2025 | 620.50 Mn |
| Sep 30, 2025 | 641.06 Mn |
| Jun 30, 2025 | 708.78 Mn |
| Mar 31, 2025 | 770.71 Mn |
| Dec 31, 2024 | 817.02 Mn |
| Sep 30, 2024 | 859.96 Mn |
| Jun 30, 2024 | 901.52 Mn |
| Mar 31, 2024 | 941.91 Mn |
| Dec 31, 2023 | 817.95 Mn |
| Sep 30, 2023 | 678.00 Mn |
| Jun 30, 2023 | 702.38 Mn |
| Mar 31, 2023 | 737.01 Mn |
| Dec 31, 2022 | 764.98 Mn |
| Sep 30, 2022 | 791.60 Mn |
| Jun 30, 2022 | 682.72 Mn |
| Mar 31, 2022 | 565.03 Mn |
| Dec 31, 2021 | 418.18 Mn |
| Sep 30, 2021 | 269.53 Mn |